9:22 AM
Leo Group India
| ||
| Onyx Pharmaceuticals Receives FDA Accelerated Approval of Kyprolis ... Equities.com Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis(TM) (carfilzomib) for Injection, a proteasome inhibitor, indicated for the treatment of patients with ... See all stories on this topic » | ||
| Ligand Licensee Onyx Pharmaceuticals Receives FDA Accelerated Approval of ... MarketWatch (press release) SAN DIEGO, Jul 20, 2012 (BUSINESS WIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that its licensee, Onyx Pharmaceuticals (NASDAQ:ONXX) , received accelerated approval from the U.S. Food and Drug Administration ... See all stories on this topic » | ||
| Onyx Pharmaceuticals Receives FDA Accelerated Approval of Kyprolis(TM ... MarketWatch (press release) SOUTH SAN FRANCISCO, Calif., July 20, 2012 /PRNewswire via COMTEX/ -- Onyx Pharmaceuticals, Inc. (NASDAQ:ONXX) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Kyprolis(TM) (carfilzomib) for ... See all stories on this topic » | ||
| Synergy Pharmaceuticals Signs Definitive Agreement to Acquire Callisto ... MarketWatch (press release) NEW YORK, Jul 20, 2012 (GlobeNewswire via COMTEX) -- Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) and Callisto Pharmaceuticals, Inc. (OBB:CLSP) announced today that they have entered into a definitive merger agreement pursuant to which Callisto ... See all stories on this topic » | ||
| ScinoPharm's Taiwan facility to provide contract manufacturing of topiramate API ... pharmabiz.com ScinoPharm, a leading process R&D and API manufacturing service provider to the global pharmaceutical industry, has announced that its Tainan, Taiwan Facility will provide commercial manufacturing of topiramate active pharmaceutical ingredient (API) for ... See all stories on this topic » | ||
| FDA approves new drug to treat blood cancer msnbc.com WASHINGTON — U.S. drug regulators approved Onyx Pharmaceuticals Inc.'s Kyprolis for people with a type of blood cancer that has failed to respond to other medicines. Don't miss these Health stories. Colorado ER doctor: 'Oh, my heart sank'. A Colorado ... See all stories on this topic » | ||
| Onyx Wins FDA Approval for Cancer Treatment Businessweek "We think this is just terrific for patients," Onyx Pharmaceuticals Inc.'s Chief Executive Officer Tony Coles said in a telephone interview today. "We are prepared to launch, we have all the necessary plans in place." Photographer: Jeremy Bales/Bloomberg ... See all stories on this topic » | ||
| AcelRx Pharmaceuticals, Inc. Investor Presentation Now Available for On ... MarketWatch (press release) NEW YORK, July 20, 2012 /PRNewswire via COMTEX/ -- AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) , a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and ... See all stories on this topic » | ||
| Onyx Wins U.S. Regulatory Approval of Blood Cancer Therapy Bloomberg Onyx Pharmaceuticals Inc. (ONXX)'s treatment for a deadly blood cancer won U.S. approval, giving the company its first wholly owned drug to sell. The medicine, called Kyprolis, was cleared for patients who have received two prior therapies, the Food and ... See all stories on this topic » | ||
| KV Pharmaceutical Company Announces Additional Notification from NYSE ... MarketWatch (press release) ST. LOUIS, July 20, 2012 /PRNewswire via COMTEX/ -- K-V Pharmaceutical Company ("the Company") today announced that on July 16, 2012 it was notified by the New York Stock Exchange Regulation, Inc., ("NYSE") that it is below listing standard criteria ... See all stories on this topic » |
This once a day Google Alert is brought to you by Google.
Delete this alert.
Create another alert.
Manage your alerts.
0 comments:
Post a Comment